He H. et al. found that 8-cetyl berberine (CBBR) not only managed to modulate different genes involved in lipid accumulation, inflammation, or steatosis, but it also downregulated the LCN2 pathway relieving metabolic changes associated with NAFLD, showing in this way that maybe BBR and its derivatives might target inflammation and progression of steatotic liver disease [117]. Here, LCN2 is linked to metabolic dysfunction-associated steatotic liver disease.